Eptinezumab
| Evidence Level: N/A | Predicted Indications: 0 |
Table of Contents
- Eptinezumab
Eptinezumab: Known uses and market status in Australia
Summary
The TxGNN model produced candidates for Eptinezumab with a score of 0.99 or higher. Every candidate that can be traced to a source is already a known use, so there is currently no new predicted indication. The one known use is in the same disease category as an approved indication, and it is not itself listed as approved.
Quick overview
| Item | Content |
|---|---|
| New predicted indications | None (all traceable model candidates are known uses) |
| Known uses among model candidates | 1 |
| Evidence level | Not applicable |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
Known uses among the model’s candidates
Approved (supported by a licence or label)
| Indication | Source |
|---|---|
| none | none |
Related to an approved indication (same disease category)
| Indication | Approved category |
|---|---|
| migraine with brainstem aura | migraine |
Relations recorded in the knowledge graph (no approval found)
| Indication |
|---|
| none |
Australia Market Information
| Licence | Product | Dosage form | Status |
|---|---|---|---|
| 13342F | Vyepti | Solution concentrate for I.V. infusion 1 | Valid |
Safety Considerations
Please refer to the TGA-approved Product Information (PI) for safety information.
Published cohort studies of CGRP inhibitors raise questions about glaucoma risk (PMID 42090640) and cerebrovascular risk, such as ischaemic stroke or TIA (PMID 42390441). These are observational safety signals, and the data compiled for this report do not allow firm conclusions.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.